Comparison of Effectiveness of Brivaracetam and Levetiracetam for Prophylaxis of Early Post-Traumatic Seizures: A Prospective Comparative Interventional Study

Overview

Journal Asian J Neurosurg

Specialty Neurology

Date 2024 Nov 28

PMID 39606308

Authors

Rajan Pandya

Ponraj Kamatchi Sundaram

Shashank Singh Baghel

Affiliations

Soon will be listed here.

Abstract

Early posttraumatic seizures (EPTS) are a major complication after a head injury, defined as seizures developing within the first 7 days of trauma. Levetiracetam has become a popular drug for the prevention of posttraumatic seizures in institutions worldwide. However, it has been reportedly associated with adverse effects like behavioral changes and somnolence. This study aimed to compare the efficacy of a newer drug, brivaracetam, which is reported to have a better pharmacokinetic profile. These findings may be significant in providing a safer yet efficacious alternative to levetiracetam. The aim of this study was to evaluate the efficacy of brivaracetam for prophylaxis of EPTS and to compare it with levetiracetam. A prospective, single-blind, parallel-group (alternate allocation) controlled trial over 100 patients admitted with traumatic brain injury in the Department of Neurosurgery, Goa Medical College, Panaji, Goa, India. The data was analyzed using IBM SPSS Statistics 29.0. Twenty patients developed EPTS in the study group: 8 from the group receiving brivaracetam and 12 from the group receiving levetiracetam. Although the brivaracetam group had a lower incidence of EPTS, the difference was not statistically significant. Eleven patients from the levetiracetam group developed side effects, while six patients from the brivaracetam group had side effects. There was no significant difference in the incidence of side effects. Brivaracetam has efficacy equal to that of levetiracetam for prophylaxis of EPTS.

References

Niespodziany I, Klitgaard H, Margineanu D . Levetiracetam inhibits the high-voltage-activated Ca(2+) current in pyramidal neurones of rat hippocampal slices. Neurosci Lett. 2001; 306(1-2):5-8. DOI: 10.1016/s0304-3940(01)01884-5. View

Xu J, Shen J, Shao W, Tang L, Sun Y, Zhai X . The safety and efficacy of levetiracetam versus phenytoin for seizure prophylaxis after traumatic brain injury: A systematic review and meta-analysis. Brain Inj. 2016; 30(9):1054-61. DOI: 10.3109/02699052.2016.1170882. View

Genton P, Van Vleymen B . Piracetam and levetiracetam: close structural similarities but different pharmacological and clinical profiles. Epileptic Disord. 2000; 2(2):99-105. View

Ghajar J . Traumatic brain injury. Lancet. 2000; 356(9233):923-9. DOI: 10.1016/S0140-6736(00)02689-1. View

Lamar C, Hurley R, Rowland J, Taber K . Post-traumatic epilepsy: review of risks, pathophysiology, and potential biomarkers. J Neuropsychiatry Clin Neurosci. 2014; 26(2):iv-113. DOI: 10.1176/appi.neuropsych.260201. View

Torbic H, Forni A, Anger K, DeGrado J, Greenwood B . Use of antiepileptics for seizure prophylaxis after traumatic brain injury. Am J Health Syst Pharm. 2013; 70(9):759-66. DOI: 10.2146/ajhp120203. View

De Smedt T, Raedt R, Vonck K, Boon P . Levetiracetam: part II, the clinical profile of a novel anticonvulsant drug. CNS Drug Rev. 2007; 13(1):57-78. PMC: 6494152. DOI: 10.1111/j.1527-3458.2007.00005.x. View

Galvagno Jr S, Nahmias J, Young D . Advanced Trauma Life Support Update 2019: Management and Applications for Adults and Special Populations. Anesthesiol Clin. 2019; 37(1):13-32. DOI: 10.1016/j.anclin.2018.09.009. View

Brandt C, Klein P, Badalamenti V, Gasalla T, Whitesides J . Safety and tolerability of adjunctive brivaracetam in epilepsy: In-depth pooled analysis. Epilepsy Behav. 2020; 103(Pt A):106864. DOI: 10.1016/j.yebeh.2019.106864. View

10.

Mula M, Trimble M, Sander J . Psychiatric adverse events in patients with epilepsy and learning disabilities taking levetiracetam. Seizure. 2004; 13(1):55-7. DOI: 10.1016/s1059-1311(03)00111-0. View

11.

Lynch B, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh S, Matagne A . The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A. 2004; 101(26):9861-6. PMC: 470764. DOI: 10.1073/pnas.0308208101. View

12.

Harden C . Safety profile of levetiracetam. Epilepsia. 2001; 42 Suppl 4:36-9. View

13.

Sharma S, Tiarks G, Haight J, Bassuk A . Neuropathophysiological Mechanisms and Treatment Strategies for Post-traumatic Epilepsy. Front Mol Neurosci. 2021; 14:612073. PMC: 7940684. DOI: 10.3389/fnmol.2021.612073. View

14.

Ryvlin P, Werhahn K, Blaszczyk B, Johnson M, Lu S . Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial. Epilepsia. 2013; 55(1):47-56. DOI: 10.1111/epi.12432. View

15.

Winblad B . Piracetam: a review of pharmacological properties and clinical uses. CNS Drug Rev. 2005; 11(2):169-82. PMC: 6741724. DOI: 10.1111/j.1527-3458.2005.tb00268.x. View

16.

Fordington S, Manford M . A review of seizures and epilepsy following traumatic brain injury. J Neurol. 2020; 267(10):3105-3111. PMC: 7501105. DOI: 10.1007/s00415-020-09926-w. View

17.

Yablon S . Posttraumatic seizures. Arch Phys Med Rehabil. 1993; 74(9):983-1001. View

18.

Milovanovic J, Jankovic S, Pejcic A, Milosavljevic M, Opancina V, Radonjic V . Evaluation of brivaracetam: a new drug to treat epilepsy. Expert Opin Pharmacother. 2017; 18(13):1381-1389. DOI: 10.1080/14656566.2017.1359260. View

19.

Pathak S, Ziechmann R, Menzer J, Hoeft A, Villanueva P . Discontinuation of Levetiracetam and Valproic Acid Due to Adverse Effects in Early Post-traumatic Seizure Prophylaxis. Cureus. 2023; 15(10):e47742. PMC: 10676217. DOI: 10.7759/cureus.47742. View

20.

Temkin N, Dikmen S, Wilensky A, Keihm J, Chabal S, Winn H . A randomized, double-blind study of phenytoin for the prevention of post-traumatic seizures. N Engl J Med. 1990; 323(8):497-502. DOI: 10.1056/NEJM199008233230801. View